ATM and neoplasm: This study identified a maximum tolerated dose (MTD) for ATM corresponding to serum gold levels above the level necessary to successfully inhibit aPKC signaling and reduce tumor growth in preclinical models, indicating the clinical relevance of ATM and gold-containing compounds for the treatment of cancers in which aPKC signaling promotes the cancer phenotype [19, 34].